What could be the mechanisms that underly the effects of GLP-1 on synaptic plasticity
Effect of glepaglutide, a longacting glucagonlike peptide2 analog, on gastrointestinal transit time and motility in patients with short bowel syndrome: findings from a randomized trial
The combined primary endpoint of death from cardiovascular disease, nonfatal myocardial infarction, or nonfatal stroke occurred in 569 (6.5%) of patients in the semaglutide group versus 701 (8.0%) of patients in the placebo group, yielding a significant hazard ratio of 0.8 for a 20% relative risk reduction
These results come from brand-name semaglutide (Wegovy) without B12
If you are interested, monitoring your blood sugar regularly can provide valuable insights into how well the medication works
Initial consultation, labs, prescription